Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance
Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
Multiplex proximity ligation assay to identify a biomarker panel for prognosis in unresectable pancreatic cancer patients treated with stereotactic body radiation therapy
Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis.
Phase 2 Study of Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy in Patients With Resectable Pancreatic Cancer
Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention
Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy
Development of a Novel Preclinical Pancreatic Cancer Research Model: Bioluminescence Image- Guided Focal Irradiation and Tumor Monitoring of Orthotopic Xenografts
Presenting comparative study PRO results to clinicians and researchers: beyond the eye of the beholder.
Burden of comorbidities is higher among elderly survivors of oropharyngeal cancer compared with controls.
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
Extended Follow-up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin Lymphomas
In Proportion: Approaches for Displaying Patient-reported Outcome Research Study Results as Percentages Responding to Treatment
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)
Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia